바이오모션 사이언스(SLXN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.42 (-8.65%), 시가총액 $0.00B, 52주 범위 $0.27 ~ $14.94.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporat
바이오모션 사이언스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
바이오모션 사이언스의 현재 주가는 $0.42 (-8.65%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오모션 사이언스의 시가총액은 약 $0.00B입니다.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in